PTEN and non-small cell lung carcinoma: These data suggest that miR-21/Pten expression alteration constitutes a novel mechanism for understanding TKI resistance in NSCLC and provide a new basis for the use of miR 21/Pten-based therapeutic strategies for reversing gefitinib resistance in NSCLC.